Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析

◆英語タイトル:Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH194959FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Flexion Therapeutics Inc (FLXN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Flexion Therapeutics Inc (Flexion) discovers, develops and commercializes pain therapies. The company’s pipeline is focused on indications that include osteoarthritis knee pain, OA pain , disease modification and acute-post operative pain. The company’s marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients facing with osteoarthritis-related knee pains. Flexion employs its proprietary microsphere technology to combine triamcinolone acetonide (TA) with a polylactic-co-glycolic acid (PLGA) matrix for formulating Zilretta. Its pipeline product candidate FX201 is being developed for treating pain caused from osteoarthritis of the knee and FX301, a NaV1.7 inhibitor in preclinical phase indicated for the treatment of acute-post operative pain. The company markets Zilretta in the US through its own sales and marketing organization and distributors. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc Key Recent Developments

Nov 04,2020: Flexion Therapeutics reports third-quarter 2020 financial results and recent business highlights
Oct 13,2020: Flexion Therapeutics announces preliminary third-quarter 2020 ZILRETTA net sales of approximately $23.6 million
Aug 05,2020: Flexion Therapeutics reports second-quarter 2020 financial results and recent business highlights
Jul 14,2020: Flexion Therapeutics announces preliminary second-quarter 2020 ZILRETTA net sales
May 07,2020: Flexion Therapeutics reports first-quarter 2020 financial results and recent business highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Flexion Therapeutics Inc – Key Facts
Flexion Therapeutics Inc – Key Employees
Flexion Therapeutics Inc – Key Employee Biographies
Flexion Therapeutics Inc – Major Products and Services
Flexion Therapeutics Inc – History
Flexion Therapeutics Inc – Company Statement
Flexion Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Flexion Therapeutics Inc – Business Description
Flexion Therapeutics Inc – Corporate Strategy
Flexion Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Flexion Therapeutics Inc – Strengths
Flexion Therapeutics Inc – Weaknesses
Flexion Therapeutics Inc – Opportunities
Flexion Therapeutics Inc – Threats
Flexion Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Flexion Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 04, 2020: Flexion Therapeutics reports third-quarter 2020 financial results and recent business highlights
Oct 13, 2020: Flexion Therapeutics announces preliminary third-quarter 2020 ZILRETTA net sales of approximately $23.6 million
Aug 05, 2020: Flexion Therapeutics reports second-quarter 2020 financial results and recent business highlights
Jul 14, 2020: Flexion Therapeutics announces preliminary second-quarter 2020 ZILRETTA net sales
May 07, 2020: Flexion Therapeutics reports first-quarter 2020 financial results and recent business highlights
Mar 12, 2020: Flexion Therapeutics reports fourth-quarter and full-year 2019 financial results
Mar 11, 2020: Flexion Therapeutics names Melissa Layman Chief Commercial Officer
Dec 10, 2019: Flexion Therapeutics announces the retirement of Neil Bodick, M.D., Ph.D., chief scientific officer and company co-founder 2019
Nov 07, 2019: Flexion Therapeutics reports third-quarter 2019 financial results and recent business highlights
Sep 10, 2019: Flexion Therapeutics licences pain therapy from Xenon
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Flexion Therapeutics Inc, Key Facts
Flexion Therapeutics Inc, Key Employees
Flexion Therapeutics Inc, Key Employee Biographies
Flexion Therapeutics Inc, Major Products and Services
Flexion Therapeutics Inc, History
Flexion Therapeutics Inc, Subsidiaries
Flexion Therapeutics Inc, Key Competitors
Flexion Therapeutics Inc, Ratios based on current share price
Flexion Therapeutics Inc, Annual Ratios
Flexion Therapeutics Inc, Annual Ratios (Cont...1)
Flexion Therapeutics Inc, Interim Ratios
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Flexion Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • InSightec Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd, is a medical device company that develops and markets magnetic resonance imaging ultrasound based medical devices. The company offers products through divisions such as neurosurgery, urology, oncology and womens’ health. Its servi …
  • ICW Group:企業の戦略・SWOT・財務分析
    ICW Group - Strategy, SWOT and Corporate Finance Report Summary ICW Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • CITIC Telecom International Holdings Ltd (1883):企業の財務・戦略的SWOT分析
    CITIC Telecom International Holdings Ltd (1883) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Shuttle Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Shuttle Pharmaceuticals Inc (Shuttle), formerly Shuttle Pharmaceuticals LLC is a developer of therapies that offers novel drugs for improving cancer treatment outcomes. The company’s pipeline products comprise therapies such as SP-2-001, SP-1-161, SP-1-003 and SP-3-001. Its therapies are use …
  • Handelsbanken Great Britain:企業の戦略・SWOT・財務分析
    Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report Summary Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Midatech Pharma US Inc-医療機器分野:企業M&A・提携分析
    Summary Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. The company’s product portfolio includes Soltamox for the treatment and prevention o …
  • Ultragenyx Pharmaceutical Inc (RARE):医療機器:M&Aディール及び事業提携情報
    Summary Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Muc …
  • PRA Health Sciences Inc (PRAH):医療機器:M&Aディール及び事業提携情報
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometri …
  • IB Pharmaceuticals Inc (INNT):製薬・医療:M&Aディール及び事業提携情報
    Summary IB Pharmaceuticals Inc (IB Pharmaceuticals), formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biotechnology company that discovers and develops novel medicines for orphan and gastroenterological disorders. The company’s pipeline includes INN-108 intended for inflammatory bowel d …
  • Toyo Tire Corp (5105):企業の財務・戦略的SWOT分析
    Toyo Tire Corp (5105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Slovenske elektrarne, a.s.-エネルギー分野:企業M&A・提携分析
    Summary Slovenske elektrarne, a.s. (Slovenske), is an electric utility company that generates, distributes and trades electricity. It also generates and markets heat and offers ancillary services to the power industry. The company generates electricity through various resources such as conventional …
  • Sisaf Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Sisaf Ltd (Sisaf) is a drug delivery company which designs and develops topical delivery systems for cosmetic, medical, and skin care applications. The company manufactures and markets products and drug delivery solutions using ProSilic, a nano-silicon technology platform. It offers ProSilli …
  • Actinium Pharmaceuticals Inc (ATNM):製薬・医療:M&Aディール及び事業提携情報
    Summary Actinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures Inc is a biopharmaceutical company that provides development of cancer immunotherapies. The company provides pipeline products such as Iomab-B that is used for hematopoietic stem cells transplantation. It provides Iomab-B through …
  • Andrew Peller Limited:企業の戦略・SWOT・財務情報
    Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report Summary Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • SecureWorks Corp (SCWX):企業の財務・戦略的SWOT分析
    SecureWorks Corp (SCWX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Semco Maritime AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Semco Maritime AS (Semco Maritime) is a project engineering company that provides design, fabrication, service and maintenance for energy projects. The company’s products include cables, glands and support systems, reducers, adaptors and blind plugs, junction boxes, signalling equipment, lig …
  • Polpharma SA-製薬・医療分野:企業M&A・提携分析
    Summary Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary …
  • SmithGroupJJR:企業の戦略・SWOT・財務情報
    SmithGroupJJR - Strategy, SWOT and Corporate Finance Report Summary SmithGroupJJR - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Florida Power & Light Co:企業の発電所・SWOT分析2018
    Florida Power & Light Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆